2024年9月10-12日·无锡·2024第三届生物偶联药全球创新峰会

2024年9月10-12日·无锡·2024第三届生物偶联药全球创新峰会-肽度TIMEDOO

由药明合联WuXi XDC和佰傲谷BioValley共同主办的2024第三届生物偶联药全球创新峰会（Global XDC 2024），将于9月10-12日在无锡重磅回归。大会涵盖2个主论坛+4个分论坛，预计参会企业300+家，参会专家100+位，参会观众1000+人。大会以“探索偶联药的无限可能”为主题，将聚焦于新靶点发现与验证、ADC和新型偶联药物创新技术、载荷-连接子新技术，以及CMC挑战和商业化策略等内容，探索前沿技术进步、分享国际优秀生物科技公司的创新经验、引领ADC和XDC的新未来！

本届峰会邀请了众多生物偶联药领域的国际专家与会，共同探讨创新合作，碰撞思想，助力生物偶联药行业蓬勃发展。

1.国际嘉宾阵容来袭，聆听偶联药的世界声音

2024年9月10-12日·无锡·2024第三届生物偶联药全球创新峰会-肽度TIMEDOO

2.精选热门议题一览，探索偶联药的无限可能

2024年9月10-12日·无锡·2024第三届生物偶联药全球创新峰会-肽度TIMEDOO

Keynote Speech

Rina-S-the missing link(er)
Protein homeostasis by dual-precision targeted protein degradation and stabilization
A novel dual-payload ADC platform to overcome payload resistance and maximize therapeutic promise of ADCs
MYTX-011: a cMET-targeting ADC engineered for anti-tumor activity against a broader spectrum of cMET expression
NTX1105: development of a best-in-class ADC targeting Nectin-4
Collaborating within the global life science ecosystem to advance breakthrough science

论坛一：Next generation ADCs: Novel targets, payloads, payload-linkers, and conjugation technologies

Next generation ADCs: novel targets, payloads, linkers and conjugation technologies
Nexatecan™: OHPAS-able Topo1 inhibitor for ADC
Introduction to PINOT-ADC platform: novel Top1 inhibitor payload, tandem cleavable and super-hydrophilic linker, and dual payload system
Versatile drug bundle-based ADC platform: achieving site-specific conjugation, DAR of 8 or 12, and dual payloads
CS5001, a potential best-in-class ROR1 ADC
Discovery of AT65474, a highly selective anti-CLDN6 ADC with a proprietary payload
Polysorbates in biopharmaceuticals-approaches to mitigate risk

论坛二：Bioconjugates development beyond ADCs

RDC-the exploration of new drug modality in unmet clinical need
Intra-cellular mutant epitopes-novel targets for ADC and bispecific antibodies?
GBB’s AI-enabled ecosystem elevating biological drug development
Developing radiopharmaceuticals targeting CLDN 18.2 with nanobodies
Fully human common light chain technology for novel ADCs

论坛三：Innovative bioconjugate discovery: from target selection to PreClinical Candidate (PCC)

Harnessing AbClick Pro^®for AT-211: leading CLDN 18.2 ADCs with superior therapeutic index
An overview on the new topoisomerases inhibitors technologies
Next generation ADCs:novel targets, payloads, linkers and conjugation technologies
Challenges and solutions for clinical PK bioanalysis of antibody drug conjugates (ADCs)

论坛四：CMC challenges and commercialization strategies

CMC scale-up challenges and COGs for site specific ADCs
Innovative bioassays: translate clinical effects into a rigorous system of XDC product assessment
The integrated analytical platform enables accelerated CMC development of XDCs
QbD considerations for ADC process
How WuXiBio’s Microbial Platform facilitates rapid and cost-effective ADC development and manufacturing
Non-clinical strategies for ADC drugs